Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
James Anthony Cannon Insider Profile
4 Followers
James Anthony Cannon, Director at Alaunos Therapeutics, holds 398.05K shares in Alaunos Therapeutics (Ticker: TCRT).
James Anthony Cannon has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of James Anthony Cannon's holdings
Insider Roles
Director
Roles that James Anthony Cannon holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by James Anthony Cannon
James Anthony Cannon's Trading History
List of latest transactions for each holding click on a transaction to see James Anthony Cannon's performance on stock
You May Also Like
James Anthony Cannon insider profile FAQ
What is the percentage of profitable transactions made by James Anthony Cannon?
The percentage of profitable transactions made by James Anthony Cannon is ―.
What is the average return per transaction made by James Anthony Cannon?
The average return per transaction made by James Anthony Cannon is ―.
What stocks does James Anthony Cannon hold?
James Anthony Cannon holds: TCRT stocks.
What was James Anthony Cannon’s latest transaction?
James Anthony Cannon latest transaction was an Uninformative Buy of $10.50K.
What was James Anthony Cannon's most profitable transaction?
James Anthony Cannon’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is James Anthony Cannon's role in Alaunos Therapeutics?
James Anthony Cannon's role in Alaunos Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.